Staff member

Colorectal cancer (CRC) ranks among the most common cancers and is the second leading cause of cancer-related deaths. The high mortality associated with CRC is attributed mainly to difficulties in early detection and lack of effective targeted therapies. The Transferrin receptor 1 (TfR1) is particularly attractive as a therapy target given its notable overexpression in tumor cells, particularly in CRC. This study explored the potential of a polymeric nanoparticle (PSomes)-based drug delivery system targeting TfR1 to improve the precision and efficacy of CRC treatment. For this study, we used two human CRC cell lines (HT-29, and HCT116), a healthy human intestinal epithelial cell line (hIECs), and a murine CRC cell line (MC38). We engineered PSomes composed of poly (ethylene glycol) (PEG) and poly (lactic acid) (PLA), functionalized with the T7 peptide to enhance their specificity for TfR1-expressing cells. Targeting efficiency of these PSomes was assessed across all cell lines by evaluating the cellular uptake using flow cytometry. Upon establishing the optimal formulation for these NPs for TfR1-targeting, we encapsulated doxorubicin (DOX) to assess their therapeutic potential. Both in vitro and in vivo experiments demonstrated that DOX loaded TfR1-targeted PSomes delivered DOX to CRC cells, leading to efficient induction of CRC cell death, reducing tumor growth and improving survival rates, compared to the control groups. These results highlight the promise of TfR1-targeted PSomes as a precise strategy for CRC therapy, offering enhanced treatment efficacy while reducing systemic toxicity. This novel approach could lead to more targeted and less harmful cancer treatments.

JTD